IMMU Stock Overview
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mendus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.49 |
| 52 Week High | kr1.85 |
| 52 Week Low | kr0.30 |
| Beta | 0.98 |
| 1 Month Change | 6.06% |
| 3 Month Change | 3.16% |
| 1 Year Change | -73.22% |
| 3 Year Change | -90.06% |
| 5 Year Change | -93.91% |
| Change since IPO | -94.24% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20
Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Shareholder Returns
| IMMU | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.9% | -0.06% | 0.9% |
| 1Y | -73.2% | -5.3% | 10.3% |
Return vs Industry: IMMU underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: IMMU underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| IMMU volatility | |
|---|---|
| IMMU Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IMMU has not had significant price volatility in the past 3 months.
Volatility Over Time: IMMU's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 30 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
| IMMU fundamental statistics | |
|---|---|
| Market cap | kr493.52m |
| Earnings (TTM) | -kr101.62m |
| Revenue (TTM) | kr28.49m |
17.3x
P/S Ratio-4.9x
P/E RatioIs IMMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMU income statement (TTM) | |
|---|---|
| Revenue | kr28.49m |
| Cost of Revenue | kr0 |
| Gross Profit | kr28.49m |
| Other Expenses | kr130.11m |
| Earnings | -kr101.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | -356.72% |
| Debt/Equity Ratio | 0.1% |
How did IMMU perform over the long term?
See historical performance and comparison